CD8A and neoplasm: By blocking the interaction of CD8+ T cell-related receptors (CTLA-4 and PD-1) and ligands (PD-L2 and PD-L1), anti-tumor immunity is enhanced in patients with advanced solid tumor, including gastric cancer [52].